Drug intelligence / Profile preview

BlueC-231

Development stage: Preclinical
Lead developer: Blue Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Parenteral

Overview

BlueC-231 is an allogeneic stem-cell therapy being developed by Blue Cell Therapeutics for the treatment of severe erectile dysfunction (ED). The therapy utilizes engineered stem cells that secrete vascular endothelial growth factor (VEGF) and various neurotrophic factors. This dual mechanism is designed to stimulate the growth of new blood vessels (angiogenesis) and facilitate the repair of damaged nerves in the penile tissue, addressing the underlying physiological causes of ED in patients who do not respond to standard oral medications.

Targets

VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on BlueC-231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlueC-231.

Explore the full profile